The makers of a popular blood pressure medication who settled class actions alleging that they violated antitrust laws have been cleared of claims that they caused $21 million in damages to one of their largest customers.

Kaiser Foundation Health Plan Inc. had sued Abbott Laboratories and Geneva Pharmaceuticals Inc. for allegedly bilking the managed health care company out of $7 million in potential savings on the purchase of Hytrin, which also relieves the symptoms of enlarged prostate glands. The suit sought triple those damages, plus attorney fees.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]